CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.
Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
上皮性卵巢癌（EOC）常在晚期被诊断，伴有癌病和不良预后。一线治疗基于联合铂类药物和紫杉烷类药物的化疗方案以及手术。超过一半的患者会面临复发的问题。为了改善结局，需要新的治疗手段，目前多种策略如免疫治疗正在EOC中进行测试。为了更好地理解EOC中的整体免疫环境，已有多项研究对TIL（肿瘤浸润淋巴细胞）（TILs）的图谱进行了解析。CD8+ TILs通常被认为是有效的抗肿瘤免疫效应细胞，免疫检查点抑制剂可以潜在地激活它们以排斥肿瘤细胞。为了综合EOC中TILs的知识，我们根据PRISMA指南对过去10年发表在MEDLINE或EMBASE中的研究进行了综述。从已发表的数据中回顾了TILs在EOC预后中的描述和作用。TILs、DNA修复缺陷和ICs之间的关联已被研究。最后，本综述描述了TILs在EOC未来免疫治疗中的作用。
Epithelial ovarian cancers (EOC) are often diagnosed at an advanced stage with carcinomatosis and a poor prognosis. First-line treatment is based on a chemotherapy regimen combining a platinum-based drug and a taxane-based drug along with surgery. More than half of the patients will have concern about a recurrence. To improve the outcomes, new therapeutics are needed, and diverse strategies, such as immunotherapy, are currently being tested in EOC. To better understand the global immune contexture in EOC, several studies have been performed to decipher the landscape of tumor-infiltrating lymphocytes (TILs).
CD8+ TILs are usually considered effective antitumor immune effectors that immune checkpoint inhibitors can potentially activate to reject tumor cells. To synthesize the knowledge of TILs in EOC, we conducted a review of studies published in MEDLINE or EMBASE in the last 10 years according to the PRISMA guidelines. The description and role of TILs in EOC prognosis are reviewed from the published data. The links between TILs, DNA repair deficiency, and ICs have been studied.
Finally, this review describes the role of TILs in future immunotherapy for EOC.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
